TherapeuticsMD, Inc.

Good morning, ladies and gentlemen. Thank you for joining us for a TherapeuticsMD fourth quarter 2020 financial results conference call. Following prepared remarks from the company, we will open the call for questions. I would now like to turn the call over to TherapeuticsMD's Vice President of Investor Relations, Nicole Oshner. Nicole?

Thank you. Good morning, everyone. Thank you for joining today to discuss our fourth quarter financial results and business update. This morning, TherapeuticsMD issued a press release announcing our fourth quarter financial results. The press release is available on the company's website, therapeuticsmd.com, in the Investors and Media section. On today's call from TherapeuticsMD are Chief Executive Officer Robert Fenizio, Chief Financial Officer James Durecka, Chief Commercial Officer Don Halkoff, and Chief Strategy and Performance Officer Mitchell Crafton. I would like to remind everyone that certain statements made during this conference call may contain forward-looking statements. Such forward-looking statements are based upon current expectations and there can be no assurance that the results contemplated in these statements will be realized. Actual results may differ materially from such statements due to a number of factors some of which are identified in our press release and our annual, quarterly, and other reports filed with the SEC. These forward-looking statements are based on information available to TherapeuticsMD today, and the company assumes no obligation to update statements as circumstances change. An audio recording and webcast replay for today's conference call will also be available online in the Investors and Media section of the company's website. For the benefit of those who may be listening to the replay or archive webcast, this call was held and recorded March 2nd, 2021. With that, I'll turn the call over to Therapeutics MD CEO, Robert Fenizio.

Good morning. On today's call, we will review our fourth quarter and full year performance. Progress made on strengthening our capital structure and our commercial plans. We delivered a strong year. and a strong quarter with record total net product revenue for our company. We successfully executed our multiple priorities demonstrating operational agility while maintaining a strict focus on commercial execution and financial discipline. We've lowered our operating expenses, updated our net revenue covenants for the remainder of the term of our loan, and strengthened our balance sheet through equity capital raises as we reduce our debt. Before I turn the call over to James to give you the detail on the transformative progress we've recently achieved, I'd also like to mention that the VitaCare divestment process is still moving forward and has multiple interested parties. I will now turn the call over to James.